David Harman focuses his practice on personal injury and mass tort litigation, including lawsuits involving defective pharmaceutical drugs and devices. David is significantly involved in the Yaz/Yasmin (Drospirenone) Products Liability Litigation (MDL 2100) representing clients who have suffered injuries as a result of their use of Bayer’s oral contraceptives Yaz, Yasmin, Ocella, and Gianvi. David also has experience working on the Testosterone Replacement Therapy (TRT) Products Liability Litigation (MDL 2545), Fosamax Products Liability Litigation (MDL 1789), and the contaminated Heparin litigation. Furthermore, David is actively involved in lawsuits against DePuy involving its Gentamicin containing bone cements used in joint replacement procedures.
Beyond David’s involvement in pharmaceutical and medical device cases, David is also experienced representing individuals in a variety of personal injury claims.
In 2014, David was invited by the National Trial Lawyers to be a member of the Top 40 Under 40 Attorneys in Ohio.
Prior to coming to Burg Simpson, David earned his Juris Doctorate from Case Western Reserve University School of Law in 2011, where he graduated magna cum laude and earned honors in his Litigation Concentration. While in law school, David externed for the Hon. Peter C. Economus, U.S. District Court, Northern District of Ohio and was a member of the school’s National Moot Court Team.
The National Trial Lawyers Top 40 Under 40 – Ohio 2014
U.S. District Court, Southern District of Ohio
J.D., 2011, Case Western Reserve University School of Law, magna cum laude
B.A., 2008, Denison University, magna cum laude
Cincinnati Bar Association
Potter Stewart American Inn of Court
Federal Bar Association
The National Trial Lawyers
The American Association for Justice
“Low-T: Creating a Problem, Manufacturing a Cure,” The Trial Lawyer magazine, 2014, Co-Author